Ionis Pharmaceuticals, Inc. IONS
26.83 USD -1.18 (-4.21%)
As ofNov 17, 2026, 2:28 PM EST
26.76 Day range 28.09
26.76 52-week range 86.74
- YTD
- -66.08%
- 1 year
- -63.37%
News
gurufocus.com TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA⢠(olezarsen) as an adjunct tobenzinga.com Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL – TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels…
businesswire.com TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in…
marketbeat.com Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more…
gurufocus.com Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 TRYNGOLZA sales fell to $9.3 million fro
globenewswire.com Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
globenewswire.com Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals, Inc. (IONS) Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation…
businesswire.com Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary…
zacks.com Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.
seekingalpha.com AMG TimesSquare Mid Cap Growth Fund Q3 2026 Portfolio Update During this quarter, AMG TimesSquare Mid Cap Growth Fund performed in line with the Russell Midcap® Growth Index. Our leading contributors were software and health care technology companies that…
defenseworld.net Ionis Pharmaceuticals (NASDAQ:IONS) Stock Falls 7.3% Following Analyst Downgrade Shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) traded down 7.3% during trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $58.00 to…benzinga.com Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41 Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.
benzinga.com Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75 Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.
benzinga.com TD Cowen Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $53 TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $84 to $53.
benzinga.com Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $70 Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $70.
globenewswire.com Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a…benzinga.com RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.
prnewswire.com IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to…benzinga.com Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80 Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
benzinga.com HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $70 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $100 to $70.
businesswire.com Ionis to present at upcoming investor conferences CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global…
benzinga.com Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals stock hits a 52-week low after halving 2026 Tryngolza guidance, despite beating Q3 earnings estimates and posting 55% revenue growth.
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…benzinga.com Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M Estimate Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.21) by 66.94 percent. This is a 34.43 percent increase over losses…
benzinga.com Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $916.396M Est Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $916.396 million estimate.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.benzinga.com BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66 BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.
